|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||106.30 - 107.99|
|52 Week Range||97.56 - 124.40|
|PE Ratio (TTM)||25.91|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
U.S. House Democrats said on Thursday they were launching an investigation into why prices for Multiple Sclerosis (MS) treatments have nearly quintupled since 2004, and they sent letters requesting information from seven drugmakers. U.S. Representatives Elijah Cummings and Peter Welch sent the letters to Bayer AG, Biogen Inc, Merck KGaA's EMD Serono unit, Novartis AG, Roche Holding AG, Sanofi SA, and Teva Pharmaceutical Industries Inc .
Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.
Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.